BioSpace News Archive

Ikena Oncology, Inc., a targeted oncology company forging new territory in patient-directed cancer treatment, announced financial results for the third quarter ended September 30, 2022.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday, November 14th.

Ceapro Inc. announced the signing of a license agreement with The Governors of the University of Alberta to use designated areas within Agri-Food Discovery Place to further scale up the Company’s disruptive Pressurized Gas eXpanded technology in preparation for commercial partnerships.

Alpha Pro Tech, Ltd. announced financial results for the three and nine month periods ended September 30, 2022.

Allotrope Medical™ Inc., a company committed to advancing surgical efficiency and safety, announced that they have received Safer Technologies Program (STeP) designation from the FDA for their surgical device StimSite.

Brand Institute is proud to announce its work with scPharmaceuticals in developing the brand name FUROSCIX®, which was approved by the FDA on October 7, 2022.

Therapeutic Solutions International (TSOI) announced today that its breast cancer focused spin-off, Res Nova Bio, Inc., initiated a collaboration with Veltmeyer MD Inc. aimed at providing access to the anti-angiogenic immunotherapy ValloVax.

Nucleai, a leader in AI-powered spatial biology, today announced the expansion of its spatial biology platform to include a new generation of multiplex immunofluorescence (mIF) analysis that uses deep learning to establish new levels of accuracy, speed, and generalizability, further unlocking the power of mIF data for drug discovery and development.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has extended its line of Haloperidol Tablets, USP and is now offering unit dose packaging in 1 mg, 5 mg, and 10 mg strengths.